This is a working overview of phase 2 trial, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-11 and is reviewed periodically as new material appears.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
This could be due to the branch point at the intermediate α-ketoisovalerate, which can be transaminated to produce valine or further acetylated to generate leucine. There may be different isotope effects associated with the addition of an amino or acetyl group at position C-2 in α-ketoisovalerate. As discussed above, the isotopic consequences of this branch point would depend on the relative rates of leucine vs valine production. One would also expect relative depletion of 13C in leucine because its synthesis requires the addition of another isotopically light acetyl group. In Escherichia coli, the carboxyl carbon in leucine (derived from acetyl-CoA) has a δ13C value roughly 13‰ lower than that of the entire molecule. Curiously, the same depletion is not observed in photoautotrophs. Further, there is little consistency in the δ13C of most amino acids between cyanobacteria and eukaryotic photoautotrophs. These discrepancies demonstrate the limits of our understanding of the mechanisms that set amino acid isotopic compositions. Regardless, isotopic variations between different taxa have been used to great effect in ecology.
In Australia, ketamine is listed as a Schedule 8 controlled drug under the Poisons Standard (October 2015). In Canada, ketamine has been classified as a Schedule I narcotic since 2005. In December 2013, the government of India, in response to rising recreational use and the use of ketamine as a date rape drug, added it to Schedule X of the Drug and Cosmetics Act, requiring a special license for sale and maintenance of records of all sales for two years. In the United Kingdom, it was labeled a Class B drug on 12 February 2014. In 2025, the Home Office requested a review of the classification with a view to changing it to Class A, based on an increase in recreational use and the negative health consequences. The increase in recreational use prompted ketamine to be placed in Schedule III of the United States Controlled Substances Act in August 1999.
Cytokines such as IL2 and IL12, essential for T cell responses, are also regulated by vitamin D. In the domain of blood coagulation, vitamin D regulates the expression of THBD (Thrombomodulin), a key gene involved in the coagulation process. Vitamin D also affects genes involved in cell differentiation and proliferation, including p21 and p27, which regulate the cell cycle, as well as transcription factors such as c-fos and c-myc, which are involved in cell proliferation.
Sources: en.wikipedia.org
=== When density varies due to both concentration and temperature === Density variation due to both concentration and temperature is an important field of study in double diffusive convection. If density changes due to both temperature and salinity are taken into account, then some more terms add to the Z-Component of momentum as follows:
High amounts of vapor particle deposition are believed to enter into the lungs with each puff because the particle size in e-cigarette vapors is within the respiratory range. After a puff, the inhaled vapor changes in the size distributions of particles in the lungs. This results in smaller exhaled particles. E-cigarette vapor is made up of fine and ultrafine particles of particulate matter. Vaping generates particulate matter 2.5 μm or less in diameter (PM2.5), but at notably less concentrations compared to cigarette smoke. Particle concentrations from vaping ranged from 6.6 to 85.0 μg/m3. Particle-size distributions of particulate matter from vaping differ across studies. The longer the puff duration the greater the amount of particles produced. The greater the amount of nicotine in the e-liquid the greater the amount of particles produced. Flavoring does not influence the particle emissions. The various kinds of devices such as cig-a-likes, medium-sized vaporizers, tanks, or mods may function at different voltages and temperatures. Thus, the particle size of the e-cigarette vapor can vary, due to the device used. Comparable to cigarette smoke, the particle size distribution mode of e-cigarette vapor ranged from 120 to 165 nm, with some vaping devices producing more particles than cigarette smoke.
dispersive replication A hypothetical mode of DNA replication in which the pairing of template strands and newly synthesized strands is not consistent within the same daughter molecule; i.e. each of the replicated daughter molecules is a heterogeneous mixture, with some segments composed of the original template strands and others composed of the newly synthesized strands. This process implies that the pairing of strands does not occur uniformly at all replication forks. Only the semiconservative mode of replication occurs naturally. See also conservative replication.
Sources: en.wikipedia.org
=== Global teaching and research === Arizona partnership with Universidad de Sonora was renewed in August 2017, focusing on a partnership in geology and physics. Arizona has been part of both theoretical and experimental research in particle and nuclear physics in the framework of the CERN program since 1987. The collaboration was initiated by the theoretician Peter A. Carruthers, head of the physics department, and Johann Rafelski who initiated the quark-gluon-plasma program at CERN. Arizona officially joined the CERN-LHC ATLAS Collaboration in 1994. Arizona has a strategic program to attract foreign scholars, in particular from China. Following a 2024 report by the United States House Select Committee on Strategic Competition between the United States and the Chinese Communist Party and the United States House Committee on Education and Workforce, Arizona closed its four micro-campuses in China.
NAD+ kinase (EC 2.7.1.23, NADK) is an enzyme that converts nicotinamide adenine dinucleotide (NAD+) into NADP+ through phosphorylating the NAD+ coenzyme. NADP+ is an essential coenzyme that is reduced to NADPH primarily by the pentose phosphate pathway to provide reducing power in biosynthetic processes such as fatty acid biosynthesis and nucleotide synthesis. The structure of the NADK from the archaean Archaeoglobus fulgidus has been determined. Since NADP(H) cannot cross subcellular membranes, eukaryotic cells have separate NADP(H) pools that are maintained by specific NAD kinases:
=== Metatropic dysplasia === Metatropic means "changing form" and refers to this form of skeletal dysplasia as there is an abnormality in the growth plates. Skeletal changes continue over time and may need surgical intervention to help protect the lungs. Symptoms starting at birth may be mild or can be fatal. There are recognizable features in individuals with this genetic disorder. Some are short stature, narrow chest, "facial features such as a prominent forehead, underdevelopment of the upper jaw, cheekbones and eye sockets (midface hypoplasia), and a squared-off jaw." It is considered a more severe skeletal dysplasia, but is very rare, with the exact number of those affected unknown. Prognosis is largely on a case-by-case basis depending on the severity, and life expectancy may not be impacted unless there are respiratory complications.
=== Dairy products === Experiments conducted by introducing the strain ME-3 of L. fermentum into dairy products as a probiotic ingredient revealed that it was able to suppress the reputed contaminants of food such as pathogenic Salmonella spp., Shigella spp., and urinary tract infections that are caused by E. coli and Staphylococcus spp. Also the introduction of L. fermentum strains such as ME-3 in goat milk revealed that it was actually favorable to the host, resulting in an increase in number of beneficial lactobacilli.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.